Instructors
Marianne Clancy, MPA
Executive Director, Cure HHT, United States
Linda S. Deal, MS
Head of Patient-Centered Outcomes Measurement, Pfizer Inc., United States
Linda currently serves as PCOA Lead working across Pfizer’s therapeutic categories addressing efforts to develop, validate and use COAs as endpoints for providing evidence of medical treatment benefit differentiation, labeling and value. Linda has served patients and the pharmaceutical industry for the past 20 years in similar roles at Wyeth, Janssen, Shire and Pfizer. Linda has developed and/or validated COAs across multiple therapeutic categories. Linda is trained as a statistician.
Susan Martin
Head, Patient Reported Outcomes, RTI Health Solutions, United States
Annabel Barbier, MD, PhD
Vice President, Clinical Development Rare Genetic Diseases, Agios Pharmaceuticals Inc, United States
Elektra Papadopoulos, MD, MPH
Director, Patient Experience Data and Strategy, AbbVie, United States
Dr. Papadopoulos serves as the Deputy Director (acting) of the Division of Clinical Outcome Assessment in the Office of New Drugs in the Center for Drug Evaluation and Research (CDER). The Division provides consultation to CDER’s Review Divisions as well as other FDA Centers on clinical outcome assessments (COAs) regarding their development, validation, interpretation and overall suitability to support labeling claims and also manages the COA drug development qualification program.
Lori McLeod, PhD
Head, Psychometrics , RTI Health Solutions, United States
Have an account?